Economic evaluation of caspofungin versus liposomal Amphotericin B for empiric antifungal treatment in patients with neutropenic fever in Italy

Value in Health

Volumn 11, Issue 5, 2008, Pages 830-841

  Stam, Wiro B ^a   Aversa, Franco ^b   Kumar, Ritesh N ^c   Jansen, Jeroen P ^d  

^a MAPI GROUP   (Netherlands)

^b UNIVERSITY OF PERUGIA   (Italy)

^c MERCK RESEARCH LABORATORIES   (United States)

^d MAPI VALUES   (United States)

Author keywords

Caspofungin; Cost effectiveness; Empiric treatment; Fungal infections; Italy; Liposomal amphotericin B

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN;

ADULT; ARTICLE; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ECONOMIC EVALUATION; FEBRILE NEUTROPENIA; FEMALE; FLUSHING; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MYCOSIS; NAUSEA; NEPHROTOXICITY; PRIORITY JOURNAL; QUALITY OF LIFE; SENSITIVITY ANALYSIS; SIDE EFFECT; SURVIVAL; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 52649163416     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2008.00324.x     Document Type: Article

References (29)

1. Beck-Sague C, Jarvis WR. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. J Infect Dis 1993 167 : 1247 51.
2. Guiot HF, Fibbe WE, 't Wout JW. Risk factors for fungal infection in patients with malignant hematologic disorders: implications for empirical therapy and prophylaxis. Clin Infect Dis 1994 18 : 525 32.
3. Bodey GP, Kontoyiannis DP, Lewis RE. Empiric antif; ungal therapy for persistently febrile neutropenic patients. Curr Treat Options Infect Dis 2002 4 : 521 32.
4. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002 34 : 730 51.
5. Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002 346 : 225 34.
6. Cagnoni PJ, Walsh TJ, Prendergast MM, et al. Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J Clin Oncol 2000 18 : 2476 83.
7. Greenberg RN, Gagnoni PJ, Wingard JR, et al. Factors associated with increased hospital costs in patients treated with lipid-based amphotericin B for empirical therapy. J Med Econ 2002 5 : 109 18.
8. Boogaerts M, Winston DJ, Bow EJ, et al. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann Intern Med 2001 135 : 412 22.
9. Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004 351 : 1391 402.
10. Bruynesteyn K, Gant V, McKenzie C, et al. A cost-effectiveness analysis of caspofungin vs. liposomal amphotericin B for treatment of suspected fungal infections in the UK. Eur J Haematol 2007 78 : 532 9.
11. Girmenia C. La terapia antifungina empirica in oncoematologia: criteri di scelta·La terapia antifungina empirica in oncoematologia: criteri di scelta. Haematol Rep 2006 2 : 1 18.
12. Ullmann AJ, Sanz MA, Tramarin A, et al. Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries. Clin Infect Dis 2006 43 : e29 38.
13. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002 34 : 7 14.
14. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999 340 : 764 71.
15. Winston DJ, Hathorn JW, Schuster MG, et al. A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. Am J Med 2000 108 : 282 9.
16. Maertens J, Raad I, Petrikkos G, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004 39 : 1563 71.
17. Micheli A, Baili P, Quinn M, et al. Life expectancy and cancer survival in the EUROCARE-3 cancer registry areas. Ann Oncol 2003 14 (Suppl. 5 v28 40.
18. kanavos P. Pharmaceutical regulation in Europe. 2002. 23-9-2002. Conference Proceeding. Available from: http://www.irpp.org/events/archive/sep02/ kanavos.pdf [Accessed September 17 2007].
19. Vitale C, Bagnis C, Marangella M, et al. Cost analysis of blood purification in intensive care units: continuous versus intermittent hemodiafiltration. J Nephrol 2003 16 : 572 9.
20. Cagnoni PJ. Liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J Antimicrob Chemother 2002 49 (Suppl. 1 S81 6.
21. Garattini L, Giuliani G, Pagano E. A model for calculating costs of hospital wards: an Italian experience. J Manag Med 1999 13 : 71 82.
22. Lyman GH, Kuderer N, Agboola O, Balducci L. Evidence-based use of colony-stimulating factors in elderly cancer patients. Cancer Control 2003 10 : 487 99.
23. de Pauw BE, Sable CA, Walsh TJ, et al. Impact of alternate definitions of fever resolution on the composite endpoint in clinical trials of empirical antifungal therapy for neutropenic patients with persistent fever: analysis of results from the Caspofungin Empirical Therapy Study. Transpl Infect Dis 2006 8 : 31 7.
24. Wingard JR, White MH, Anaissie E, et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin Infect Dis 2000 31 : 1155 63.
25. Clark AD, McKendrick S, Tansey PJ, et al. A comparative analysis of lipid-complexed and liposomal amphotericin B preparations in haematological oncology. Br J Haematol 1998 103 : 198 204.
26. Fleming RV, Kantarjian HM, Husni R, et al. Comparison of amphotericin B lipid complex (ABLC) vs. ambisome in the treatment of suspected or documented fungal infections in patients with leukemia. Leuk Lymphoma 2001 40 : 511 20.
27. Cannon JP, Garey KW, Danziger LH. A prospective and retrospective analysis of the nephrotoxicity and efficacy of lipid-based amphotericin B formulations. Pharmacotherapy 2001 21 : 1107 14.
28. Kuti JL, Kotapati S, Williams P, et al. Pharmacoeconomic analysis of amphotericin B lipid complex versus liposomal amphotericin B in the treatment of fungal infections. Pharmacoeconomics 2004 22 : 301 10.
29. Wingard JR, Leather HL, Wood CA, et al. Pharmacoeconomic analysis of caspofungin versus liposomal amphotericin B as empirical antifungal therapy for neutropenic fever. Am J Health Syst Pharm 2007 64 : 637 43.